TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Francois-Clement Bidard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.